@article{f7fda00d0ea5460f9771cfd65fd7ef87,
title = "Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity",
abstract = "Cells respond to stimuli by changes in various processes, including signaling pathways and gene expression. Efforts to identify components of these responses increasingly depend on mRNA profiling and genetic library screens. By comparing the results of these two assays across various stimuli, we found that genetic screens tend to identify response regulators, whereas mRNA profiling frequently detects metabolic responses. We developed an integrative approach that bridges the gap between these data using known molecular interactions, thus highlighting major response pathways. We used this approach to reveal cellular pathways responding to the toxicity of alpha-synuclein, a protein implicated in several neurodegenerative disorders including Parkinson's disease. For this we screened an established yeast model to identify genes that when overexpressed alter alpha-synuclein toxicity. Bridging these data and data from mRNA profiling provided functional explanations for many of these genes and identified previously unknown relations between alpha-synuclein toxicity and basic cellular pathways.",
author = "Esti Yeger-Lotem and Laura Riva and Su, {Linhui Julie} and Gitler, {Aaron D.} and Cashikar, {Anil G.} and King, {Oliver D.} and Auluck, {Pavan K.} and Geddie, {Melissa L.} and Valastyan, {Julie S.} and Karger, {David R.} and Susan Lindquist and Ernest Fraenkel",
note = "Funding Information: E.Y.-L. has been supported by an EMBO long-term postdoctoral fellowship and by a research grant from the National Parkinson Foundation. L.R. has been supported by Roberto Rocca doctoral fellowship and the CSBi Merck-MIT postdoctoral fellowship. L.J.S. was supported by an American Cancer Society postdoctoral fellowship. A.D.G. was a Lilly Fellow of the Life Sciences Research Foundation. M.L.G is supported by a research grant from the National Parkinson Foundation. S.L. is a founder of and has received consulting fees from FoldRx Pharmaceuticals, a company that investigates drugs to treat protein folding diseases. A.D.G., A.G.C. and S.L. are inventors on patents and patent applications that have been licensed to FoldRx. E.F. is the recipient of the Eugene Bell Career Development Chair. This work was supported in part by HHMI and by MGH/MIT Morris Udall Center of Excellence in PD Research NS38372. We thank M. Taipale, S. Treusch and G. Caraveo Piso for helpful discussions and comments and T. DiCesare for help with figures. L.R. thanks G. Casari and S. Cerutti for support and helpful discussions.",
year = "2009",
month = mar,
day = "1",
doi = "10.1038/ng.337",
language = "English",
volume = "41",
pages = "316--323",
journal = "Nature Genetics",
issn = "1061-4036",
publisher = "Nature Publishing Group",
number = "3",
}